Israel Englander Apellis Pharmaceuticals, Inc. Call Options Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $28,840 - $41,150	-1,000 Reduced 5.38%	17,600 $507,000
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $1.2 Million - $1.87 Million	-31,400 Reduced 62.8%	18,600 $713,000
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $4.18 Million - $5.47 Million	-75,500 Reduced 60.16%	50,000 $2.94 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $1.24 Million - $2.16 Million	33,300 Added 36.12%	125,500 $7.51 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $4.77 Million - $5.8 Million	62,200 Added 207.33%	92,200 $8.4 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $1.4 Million - $2.01 Million	30,000 New	30,000 $1.98 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.62B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.